Bioequivalence of two tacrolimus formulations under fasting conditions in healthy male subjects

Clinical Therapeutics

Volumn 33, Issue 9, 2011, Pages 1105-1119

  Mathew, Philip ^a   Mandal, Jayanta ^b   Patel, Kamlesh ^a   Soni, Kshitij ^a   Tangudu, Geetanjali ^a   Patel, Rakesh ^a   Kale, Prashant ^a  

^a Lambda Therapeutic Research Ltd   (India)

^b Astron Research   (India)

Author keywords

Bioequivalence; Immunosuppressant; Macrolide; Pharmacokinetic; Tacrolimus; Transplantation

Indexed keywords

GENERIC DRUG; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; BODY ACHE; CHILL; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG SAFETY; EPIGASTRIC PAIN; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PAIN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TACROLIMUS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 80052977493     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.07.010     Document Type: Article

References (27)

1. Jain A., Singhal A., Fontes P., et al. One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17-to 20-year longitudinal follow-up. Transplantation 2011, 91:1025-1030.
2. Kramer B.K., Montagnino G., del Castillo D., et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005, 20:968-973.
3. Skalická B., Málek I., Kubánek M., et al. Long-term efficacy and safety of conversion to tacrolimus in heart transplant recipients with ongoing or recurrent acute cellular rejection. Physiol Res 2010, 59:379-384.
4. Jiang H., Suguo H., Takahara S., et al. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. Transplant Proc 1991, 23:2933-2936.
5. Liu J., Farmer J., Lane W., et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66:807-815.
6. Prograf [product monograph] 2005, Astellas Pharma Canada, Inc, Markham, Ont.
7. Venkataramanan R., Jain A., Warty V.W., et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc 1991, 23:931-933.
8. Undre N.A., Stevenson P., Schäfer A. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc 1999, 31:21S-24S.
9. Jørgensen K., Povlsen J., Madsen S., et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002, 17:1487-1490.
10. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004, 43:623-653.
11. Steiner R.W., Feist A.A. The "generic" effect of food on tacrolimus pharmacokinetics. Clin Transplant 2011, 25:334-335.
12. CHMP guideline on the investigation of bioequivalence CHMP/EWP/QWP/1401/98 Rev 2, Accessed July 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003011.pdf.
13. Shaw L.M., Holt D.W., Paul Keown P., et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther 1999, 21:1632-1652.
14. CHMP Efficacy Working Party Therapeutic Subgroup on Pharmacokinetics (EWP-PK) Questions & Answers: Positions on specific questions addressed to the EWP Therapeutic Subgroup on Pharmacokinetics EMA/618604/2008 Rev 2, Accessed July 2011. http://www.rsihata.com/updateguidance/2010/WC500002963.pdf.
15. CHMP guideline on the investigation of bioequivalence CPMP/EWP/QWP/1401/98 Rev 1/corr, Accessed July 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
16. ICH Topic E 6 (R1) Guideline for Good Clinical Practice European Medicines Agency, Accessed June 25, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf.
17. Guidance for industry. Bioanalytical method validation US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Accessed June 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
18. Chow S.C., Liu J.P. Design and Analysis of Bioavailability and Bioequivalence Studies 2000, Marcel Dekker Inc, New York, NY. 2nd ed.
19. CHMP guideline on the investigation of bioequivalence European Medicines Agency, Accessed July 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002963.pdf.
20. Kim S.J., Huh K.H., Han D.J., et al. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. Transplant Proc 2009, 41:1671-1674.
21. Guleria S., Kamboj M., Chatterjee A., et al. Generic tacrolimus (Pan Graf) in renal transplantation: an experience of 155 recipients in India. Transplant Proc 2008, 40:2237-2239.
22. Müller H., Solari S., Zuñiga C., et al. Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile. Transplant Proc 2008, 40:705-707.
23. Jusko W.J., Thomson A.W., Fung J.J., et al. Consensus document: therapeutic monitoring of tacrolimus (FK506). Ther Drug Monit 1995, 17:606-614.
24. McMaster P., Mirza D.F., Ismail T., et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995, 17:602-605.
25. Tsunoda S.M., Aweeka F.T. Drug concentration monitoring of immunosuppressive agents. Focus on tacrolimus, mycophenolate mofetil and sirolimus. BioDrugs 2000, 14:355-369.
26. Wallemacq P., Armstrong V.W., Brunet M., et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European Consensus Conference. Ther Drug Monit 2009, 31:139-152.
27. Tacrolimus Intas 0.5 mg [summary of product characteristics] November 2010, Intas Pharmaceuticals Ltd, Ahmedabad, India.